Abstract:Leptomeningeal metastasis (LM) is an increasingly common, fatal complication of breast and lung cancer. Despite aggressive treatment, neurologic deficits accumulate rapidly, and patients generally succumb to LM within months. We must expand our limited mechanistic knowledge of this disease. Under homeostatic conditions, choroid plexus (ChP), highly vascularized structures within the brain ventricles, restrict the entry of macromolecules and cells into the leptomeninges; however, select cancer cells can cross this barrier and grow within the leptomeningeal space. We hypothesize that interactions between cancer and ChP niche cells alter both the niche and the cancer cells, ultimately supporting LM.During neurogenesis, the ChP display substantial extracellular matrix (ECM) remodeling, which is elegantly modulated by dynamic spatiotemporal regulation of MMPs, Wnt signaling, among other effector proteins. Similarly, 2-photon imaging of ChP collected from mice harboring LM revealed a profound ECM remodeling of the ChP when compared with naïve mice. This remodeling was accompanied by increased levels of MMP2 and MMP9 in LM mice. Upon pharmacological inhibition of MMP2 and MMP9 in vivo, we observed a decrease in LM burden and increase in overall survival, which correlates with a decrease in ChP permeability. Interestingly, human CSF from patients with leptomeningeal metastases is also enriched in collagen 1 fragments, MMP2, MMP9 and TIMP1. TIMP1, a MMP9 natural inhibitor, is not present in complex with MMP9, suggesting a role of TIMP1 as a cytokine in LM progression. TIMP1 neutralization and knockout from the cancer cells leads to a decrease in LM burden and increase in overall survival. Together, these data suggest a provocative link between proteolysis and inflammation in LM progression. The use of clinically-annotated human samples and mouse models of LM, and the integration of transcriptomics and proteomics enabled us to identify key signaling pathways, and capture the re-programming of ChP niche and cancer cells that unlock the leptomeningeal space to cancer cells. The timeframe for this evolution will be further revealed by analysis of mouse and human samples at different stages of cancer progression. Citation Format: Ana Rita Nobre, Helen Wang, Rachel Estrera, Isaiah Osei-Gyening, Adrienne Boire. Unveiling the re-programming of choroid plexus and leptomeningeal metastasis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1492.

Angi-04. Distinct Expression Of Target Molecules Between Tumor Cells In Cerebrospinal Fluid And Leptomeninges For Leptomeningeal Metastasis

Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases.

LMD-03. Single Cell Analysis Reveals How Therapy Remodels the Tumor Microenvironment in Melanoma CNS Metastases and Uncovers a Novel Predictor of Improved Survival

A Preclinical Model of Patient-Derived Cerebrospinal Fluid Circulating Tumor Cells for Experimental Therapeutics in Leptomeningeal Disease from Melanoma.

Multi-Omic Characterization of Single Cells and Cell-Free Components Detected in the Cerebrospinal Fluid of Patients with Leptomeningeal Disease

Single‐cell RNA Sequencing Reveals the Characteristics of Cerebrospinal Fluid Tumour Environment in Breast Cancer and Lung Cancer Leptomeningeal Metastases

Tmic-01. Targetable Gene Expression Changes Mediate Extravasation Of Breast Cancer Cells From The Circulation And Local Proliferation In The Brain

BSLD-06 UNVEILING THE RE-PROGRAMMING OF CHOROID PLEXUS AND LEPTOMENINGEAL METASTASIS

Deciphering Biomarkers for Leptomeningeal Metastasis in Malignant Hemopathies (Lymphoma/Leukemia) Patients by Comprehensive Multipronged Proteomics Characterization of Cerebrospinal Fluid

Circulating Tumor Cell Characterization of Lung Cancer Brain Metastasis in the Cerebrospinal Fluid Through Single-Cell Transcriptome Analysis

Abstract 5529: Mimicking CAFs, pial cells support leptomeningeal metastasis

Abstract 1492: Unveiling the re-programming of choroid plexus and leptomeningeal metastasis

Circulating tumor cell characterization of lung cancer brain metastases in the cerebrospinal fluid through single‐cell transcriptome analysis

Different Metabolomic and Proteomic Profiles of Cerebrospinal Fluid in Ventricular and Lumbar Compartments in Relation to Leptomeningeal Metastases

Unique Genomic Alterations of Cerebrospinal Fluid Cell-Free DNA Are Critical for Targeted Therapy of Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

Cerebrospinal fluid circulating tumor DNA for the detection and characterization of leptomeningeal metastasis in non-small cell lung cancer.

Single-Cell Map of Diverse Immune Phenotypes in the Metastatic Brain Tumor Microenvironment of Non Small Cell Lung Cancer

Angi-06. Cerebrospinal Fluid May Be The Most Important Pathway For Brain Metastases: A Data-Driven Hypothesis And Clinical Implications

BIOM-04. CORRELATIVE PERFORMANCE OF CEREBROSPINAL FLUID (CSF) CIRCULATING TUMOR CELLS (CTC) AND CELL-FREE TUMOR-DERIVED DNA (CTDNA) IN LEPTOMENINGEAL METASTASES (LM) AND PARENCHYMAL BRAIN METASTASES (BM)

Cerebrospinal Fluid Exosomal Micrornas As Biomarkers for Diagnosing or Monitoring the Progression of Non-Small Cell Lung Cancer with Leptomeningeal Metastases

WITHDRAWN: Unique genomic alterations of cerebrospinal fluid cell-free DNA are critical for targeted therapy of non-small cell lung cancer with leptomeningeal metastasis